双嘧达莫：其对急性心肌梗死疗效的对照试验。
Dipyridamole: a controlled trial of its effect in acute myocardial infarction.
作者信息
Gent A E, Brook C G, Foley T H, Miller T N
出版信息
Br Med J. 1968 Nov 9;4(5627):366-8. doi: 10.1136/bmj.4.5627.366.
Abstract
A controlled trial of oral dipyridamole in 103 patients with acute myocardial infarction showed no difference in the number of complications or deaths in either the control or the treated groups. It is concluded that dipyridamole has no benefit in acute myocardial infarction.
摘要
一项针对103例急性心肌梗死患者的口服双嘧达莫对照试验表明，对照组和治疗组在并发症数量或死亡人数方面均无差异。得出的结论是，双嘧达莫对急性心肌梗死无益处。
相似文献
1
Dipyridamole: a controlled trial of its effect in acute myocardial infarction.双嘧达莫：其对急性心肌梗死疗效的对照试验。
Br Med J. 1968 Nov 9;4(5627):366-8. doi: 10.1136/bmj.4.5627.366.
2
Myocardial infarction associated with recurrent pulmonary embolism in a young woman.
Am J Cardiol. 1962 Apr;9:614-8. doi: 10.1016/0002-9149(62)90082-6.
3
4
[Antiaggregant effect of slow-release dipyridamole in acute myocardial infarct].
Minerva Cardioangiol. 1988 Jul-Aug;36(7-8):347-50.
5
[Rsearch into the inhibitory effect of dipyridamole on the adhesion and clumping of blood platelets "in vitro" and "in vivo"].
Ann Cardiol Angeiol (Paris). 1975 Jan-Feb;24(1 SUPPL):1-36.
6
Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction.
JAMA. 1972 Oct 30;222(5):541-8. doi: 10.1001/jama.222.5.541.
7
[Clinical application and evaluation of anti-platelet agents].
Nihon Rinsho. 1978 Dec 10;36(12):3884-94.
8
The Coronary Drug Project. Initial findings leading to modifications of its research protocol.
JAMA. 1970 Nov 16;214(7):1303-13.
9
[Use of dipyridamol in the acute period of myocardial infarction].
Vrach Delo. 1977 Jan(1):38-43.
10
[Possibility of psychic disturbances following administration of persantin].
Wiad Lek. 1971 May 1;24(9):885-7.
引用本文的文献
1
Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era.为何不使用双嘧达莫：当前指南的回顾与现代时代应用价值的再评估。
Cardiovasc Drugs Ther. 2022 Jun;36(3):525-532. doi: 10.1007/s10557-021-07224-9. Epub 2021 Jul 10.
2
THE PATHOGENESIS OF PULMONARY ARTERIOSCLEROSIS: PROPHYLAXIS WITH DRUGS WHICH AFFECT PLATELET AGGREGATION.肺动脉硬化的发病机制：使用影响血小板聚集的药物进行预防。
Cardiovasc Dis. 1974;1(2):137-152.
3
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.用于卒中二级预防的抗血小板药物的临床药代动力学
Clin Pharmacokinet. 2003;42(10):909-20. doi: 10.2165/00003088-200342100-00003.
4
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.英格兰北部循证指南制定项目：初级保健中阿司匹林用于血管疾病二级预防的指南。英格兰北部阿司匹林指南制定小组。
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
5
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I：各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
6
Platelets, thrombosis and drugs.血小板、血栓形成与药物。
Drugs. 1975;9(1):19-76. doi: 10.2165/00003495-197509010-00003.
7
Antithrombotic drugs: part II.抗血栓药物：第二部分。
Drugs. 1976;12(2):132-57. doi: 10.2165/00003495-197612020-00002.
8
Antiplatelet agents in coronary disease: are they of prophylactic value?冠心病中的抗血小板药物：它们具有预防价值吗？
Drugs. 1978 Jun;15(6):464-71. doi: 10.2165/00003495-197815060-00004.
9
Antiplatelet agents: a review.抗血小板药物：综述
J R Soc Med. 1979 Jul;72(7):513-9. doi: 10.1177/014107687907200710.
10
Antiplatelet drugs: clinical pharmacology and therapeutic use.抗血小板药物：临床药理学与治疗应用。
Drugs. 1979 Dec;18(6):439-77. doi: 10.2165/00003495-197918060-00002.
本文引用的文献
1
LONG TERM DIPYRIDAMOLE THERAPY OF ANGINA PECTORIS.
Am J Cardiol. 1965 Aug;16:234-7. doi: 10.1016/0002-9149(65)90478-9.
2
COMPARATIVE EFFECTIVENESS OF ADENOSINE ANALOGUES AS INHIBITORS OF BLOOD-PLATELET AGGREGATION AND AS VASODILATORS IN MAN.腺苷类似物作为人血小板聚集抑制剂和血管扩张剂的比较效果
Nature. 1965 Feb 13;205:678-80. doi: 10.1038/205678a0.
3
EFFECT OF CORONARY VASODILATOR DRUGS ON RETROGRADE FLOW IN AREAS OF CHRONIC MYOCARDIAL ISCHEMIA.冠状动脉扩张剂对慢性心肌缺血区域逆向血流的影响。
Circ Res. 1964 Oct;15:355-64. doi: 10.1161/01.res.15.4.355.
4
INFLUENCE OF A PYRIMIDOPYRIMIDINE DERIVATIVE ON DEAMINATION OF ADENOSINE BY BLOOD.一种嘧啶并嘧啶衍生物对血液中腺苷脱氨基作用的影响。
Circ Res. 1964 Jul;15:83-8. doi: 10.1161/01.res.15.1.83.
5
INHIBITION BY ADENOSINE AND BY 2-CHLOROADENOSINE OF THE FORMATION AND EMBOLIZATION OF PLATELET THROMBI.腺苷及2-氯腺苷对血小板血栓形成和栓塞的抑制作用
Nature. 1964 May 23;202:761-5. doi: 10.1038/202761a0.
6
PERSANTIN-- A DOUBLE BLIND STUDY.潘生丁——一项双盲研究。
Angiology. 1964 Jun;15:290-2. doi: 10.1177/000331976401500608.
7
A LONG-TERM THERAPY OF ISCHEMIC HEART DISEASE.
Angiology. 1963 Sep;14:484-9. doi: 10.1177/000331976301400909.
8
The effect of Segontin, Persantin and nitroglycerin on the coronary artery. Experimental studies with cinecoronarography.
Ann Med Exp Biol Fenn. 1962;40:423-6.
9
10
Enzymatic deamination and vasodepressor effects of adenosine analogs.腺苷类似物的酶促脱氨基作用和血管降压效应。
J Pharmacol Exp Ther. 1952 Nov;106(3):291-302.
Zotero 插件